Commercializing personalized medicine

Phyllis Whiteley from Mohr Davidow Ventures spoke at today's Commercializing Arizona Life Sciences. The theme of the impacts of personalized medicine focused on impacts on patients, payors and healthcare economics. One interesting point from the VC's perspective was that the true benefit and success factor is combination of diagnostic, data, and therapeutic. From our perspective this means an interesting challenge for product development and regulatory. Mission3 OnDemand's ability to simultaneously handle combination and adhoc submissions makes it a great choice for personalized mediciine companies.
As medicine changes - the investment in Mission3 OnDemand is not only secure but critical.